|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed specimens from patients with diabetic nephropathy (DN), FSGS, IgA nephropathy (IgAN), membranoproliferative GN (MPGN) (<i>n</i>=19-23 for each disease), and a control group (<i>n</i>=14).
|
28663230 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Focal segmental glomerular sclerotic lesions in IgA nephropathy (IgAN), considered for years a chronic histologic feature related to proteinuria in remnant nephrons without any active role in the pathogenesis and progression of glomerular damage of IgAN, have been recently reconsidered.
|
31773265 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The efficacy and safety of glucocorticoids for the treatment of patients with IgA nephropathy (IgAN) remains controversial.
|
30843135 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is primarily resulted of qualitative abnormality of IgA.
|
31815288 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The serum immunoglobulin A (IgA)/C3 ratio is considered to be an effective predictor of IgA nephropathy (IgAN).
|
31039758 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renal biopsy specimens were obtained from five patients with IgA nephropathy (IgAN), five patients with membranous nephropathy (MN) and five kidney transplant donors (as controls).
|
31707756 |
2020 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the commonest global cause of glomerulonephritis.
|
31296183 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) as the commonly used renin-angiotensin aldosterone system inhibitor are widely used in patients with IgA nephropathy (IgAN), but the effect is controversy.
|
31700813 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background</b>: Circulating B cells are crucial for the pathogenesis of IgA nephropathy (IgAN).
|
31670996 |
2020 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prognosis of patients with allograft IgA nephropathy (IgAN) requires further investigation.
|
29718591 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, but etiology and pathogenesis continue to be poorly understood.
|
29069743 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common and heterogeneous glomerular nephropathy.
|
30902505 |
2020 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is a mesangial proliferative glomerulonephritis which often shows proteinuria, an indicator for podocyte damage.
|
31600491 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is controversy over whether IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis (HSPN) are the same diseases.
|
31468231 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple genetic and environmental factors together contribute to the risk of IgA nephropathy (IgAN).
|
29069794 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is characterized by high serum IgA levels and IgA deposition in the renal mesangium.
|
29312588 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among 42 patients, podocin was normally expressed in glomeruli in purpura nephritis, IgA nephropathy (IgAN), and minimal-change disease (MCD), while it was either decreased or absent in most subjects with focal segmental glomerulosclerosis (FSGS).
|
14633131 |
2003 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the downregulation of plasma-miRNA signature was not detected in disease controls (n = 119) such as IgA nephropathy (IgAN), mesangial proliferative glomerulonephritis (MSPGN), and membranous nephropathy (MN), and the miRNA panel discriminated between FSGS and disease controls.
|
29748623 |
2018 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and has a broad range of histological and clinical manifestations, ranging from morphologically normal to globally sclerotic glomeruli with clinical manifestations varying from isolated hematuria to end stage renal disease.
|
31320251 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the leading primary GN worldwide.
|
31444275 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is a tonsil-related disease.
|
31088610 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A group of 27 patients with IgA nephropathy (IgAN) and persistent microhematuria, and another group of 20 healthy subjects without known renal diseases were selected as control groups.
|
9734616 |
1998 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide and a major cause of chronic kidney disease and failure.
|
31402200 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous genome-wide association studies have discovered significant association at ITGAX-ITGAM on 16p11.2 for IgA nephropathy (IgAN).
|
31227791 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice rendered genetically incapable of expressing UG develop a form of renal disease that closely resembles human IgA nephropathy (IgAN).
|
16703373 |
2006 |